about
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis.Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotRegulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHDRepeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignanciesChronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation.Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantationFactors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemiaHigh donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCTHigh PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia.Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation.Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyEx vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.Management of relapse after allo-SCT for AML and the role of second transplantation.An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.Diagnosis and treatment of cytomegalovirus 2013.Immunotherapy for viral and fungal infections.New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease.T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization.Hydroa Vacciniforme-like Skin Lesions in Epstein-Barr-Virus-associated T-cell Lymphoproliferation with Subsequent Development of Aggressive NK/T-cell Lymphoma.Interactions of donor sources and media influence the histo-morphological quality of full-thickness skin models.Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features.Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant.Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with RCSD1-ABL1-positive acute lymphoblastic leukemia.Life-threatening infection caused by daptomycin-resistant Corynebacterium jeikeium in a neutropenic patient.Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series.Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus.Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease.Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.Expression of the c-erbB-2-encoded oncoprotein p185 (HER-2/neu) in pregnancy as a model for oncogene-induced carcinogenesis.
P50
Q30994673-1D91E1BA-020A-476B-ADEB-A8D91976CE6AQ33416874-DD1E0255-8D6E-4F0C-B9C4-841A1B0CB975Q33558780-EBF6413D-3D16-455A-9FE0-8A364938EFD6Q33830964-DCE4834E-9D4C-4BE1-9D8F-D41B4E6340EFQ34180369-C05BF3F5-3CB8-4629-AD47-C901DE86074DQ34292984-6506CBD4-0062-44F3-83A6-3CB960BB3657Q34612637-DF83D62B-CC01-4DA5-9049-A832D357762EQ35231607-AF2C78F8-FDD4-4107-9F8D-73FA50E2A155Q35745142-B880F2A4-06F3-4E7A-AE87-C4F07B0065DDQ35847930-C7D32B31-78F2-48B4-9FB9-EFCC0A983285Q35848663-0135357C-F284-4D62-B39F-71ABA796BC9EQ35849935-7B6BABFB-2A19-4ADA-A0F5-15514629A910Q35900929-9225F1BE-742F-4DB1-8F9B-C591170EADEBQ35989456-95EDE4B4-57DA-4F00-A85C-131CDA334E34Q35989486-96675506-CE0B-4F7F-BAD6-43E37363F635Q35990687-81DB65B3-D30C-4996-BA8B-4B61C67A3077Q36185219-42C523F6-F982-4D17-BB9F-AA212C397EA9Q36384606-7A66FDC1-4585-499C-BA2E-D5897E9AF3F4Q36528822-D0A69F45-75A5-4761-B420-9685A30DC9E4Q36862931-6E8DC007-903B-45FA-A70F-576E46ACEC85Q37119922-CC98CA6E-C636-4BF2-82B4-84971560C679Q37621258-60A8191A-713C-4643-B2AF-EBFFF3F8A46FQ37624364-6BB95368-94E5-4313-852B-8D4DB304A855Q38119843-66794C30-E4F4-4A93-B8CB-936088D87309Q38258114-91E5757E-86F5-4D32-9488-7841BEB5E76DQ38514499-21A1C791-4FE9-4AEF-8179-DAE3A80AEB62Q38849186-8076D4D3-E870-4AD0-9727-BD2B1555F238Q40338962-494C3805-CF3A-4D4E-8229-7A821F2B5389Q40458963-DAF719E1-540B-45BC-8F3E-F17ACE79669CQ40593025-105A7533-D688-4E3B-8221-4F2ADBE34624Q40596630-5A13BC6B-D668-4DB6-9E56-A453D3C29858Q41715517-48B5DDEB-9211-4CFD-B4E1-EF939D3BE444Q42361901-F4ABCFBE-71E3-477C-9AE6-ED4427AE3DA3Q43097214-9DBB9256-C105-4C66-9D9E-C1B1A0640B5DQ43249320-5BC303A6-4BA9-4384-AC56-871779BB9DDAQ43413019-3131F3B6-BF27-4FE6-9C4B-94789330C4E3Q44919804-B57FC71E-878C-45C6-9B78-7ADACA4BE03EQ46464628-CEC6FB16-1FBA-44CE-B860-182BF8ECE16BQ46586635-F9DCE8CA-80D3-430D-B44B-0C643E4C6B12Q47775344-713EE2B5-6F2F-4648-A8FF-1C0F091220ED
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stephan Mielke
@ast
Stephan Mielke
@en
Stephan Mielke
@es
Stephan Mielke
@nl
Stephan Mielke
@sl
type
label
Stephan Mielke
@ast
Stephan Mielke
@en
Stephan Mielke
@es
Stephan Mielke
@nl
Stephan Mielke
@sl
prefLabel
Stephan Mielke
@ast
Stephan Mielke
@en
Stephan Mielke
@es
Stephan Mielke
@nl
Stephan Mielke
@sl
P108
P106
P108
P1153
10243860800
P21
P31
P496
0000-0002-8325-9215